Search PubMed⌕ Search

Biomedical subjects

B Mariańska

Publications and source records attributed to B Mariańska.

At least 19 recordsLinked to original sources
PubMed1998

[Preliminary treatment results of relapsed or refractory acute leukemia using two and three drug regimens].

36 patients with relapsed (29) or refractory (7) acute lymphoblastic or nonlymphoblastic leukaemia received regimens employing 1-3 courses of mitoxantrone (or idarubicin), intermediate doses of cytarabine and etoposide. Complete remission (CR) was achieved in 30% of patients (5/15 ALL, 6/21 AML, 5 cases of refractory and 6 of relapsed leukaemia). Duration of CR was 3-6+ months (3 patients are still alive). Toxicity of the treatment was acceptable, however 5 patients with severe granulocytopenia died from sepsis.

Adult↗
PubMed1998

[The analysis of factors which affect qualification of pregnant women as cord blood donors].

Authors' analysis refers to reasons for which some women did not meet criteria for the programme of collection of cord blood by The Cord Blood Bank in Warsaw. The main reasons were: 1) reactivation of infection with CMV virus, 2) complications of delivery and 3) technical problems. We present also preliminary results of blood tests aimed at identification of some viral (hepatitis B and C, HIV, CMV), bacterial (Treponema pallidum) and protozoal infections (Toxoplasma) in the selected group of pregnant women.

Adult↗
PubMed1996

[Unclassified chronic myeloproliferative Ph(-); i(17q); +8 syndrome with mixed myelo-megakaryoblastic crisis--case report].

We present a case of a 17-year old patient with extreme hepatosplenomegaly, hyperthrombocytosis, hyperleucocytosis and the presence of myelo- and megakaryoblasts in the peripheral blood film. Numerous complications that occurred in the course of the disease made cytostatic treatment difficult. Since Ph chromosome and hybrid gene bcr/abl were absent, the diagnosis of unclassified chronic myeloproliferative syndrome in the phase of blast crisis was established. Immunophenotyping confirmed a mixed myelo- megakaryoblastic character of the crisis. In the differential diagnosis other myeloproliferative syndromes were taken into account including i(17q) syndrome. The patient died after a 13-month observation due to neoplasm progression and sepsis.

Adolescent↗
PubMed1993

[Diagnostic value of acidified glycerol lysis test (AGLT) in hereditary spherocytosis and selected hematologic diseases].

AGLT and osmotic fragility test (method according to Dacie) were performed in patients with hereditary spherocytosis, their relatives and in patients with other hematological diseases. Abnormal results of both tests were observed not only in all cases of hereditary spherocytosis but also in other patients with spherocytes present in the peripheral blood film. In our opinion, AGLT is a good screening test for hereditary spherocytosis and can replace the more time consuming Dacie's method.

Hematologic Diseases↗
PubMed1991

[Morphological changes in peripheral blood and bone marrow in patients with myelodysplastic syndromes].

In 23 patients with myelodysplasia syndromes cytomorphological examinations of peripheral red blood cells and bone marrow cells were carried out. Apart from anisocytosis and poikilocytosis observed in all patients, the most frequent changes were macrocytosis and megalocytosis or erythrocytes and their precursors, presence of erythroblasts in peripheral blood and disturbances of megakaryopoiesis. None of these changes was characteristic in a given type of these syndromes.

Adult↗
PubMed1991

[Results of selected cytochemical studies of mature granulocytes in myelodysplastic syndromes and various other hematologic diseases].

The activity of alkaline phosphatase and peroxidase was measured in polymorphonuclears in 20 cases of myelodysplasia syndromes, 10 cases of chronic myeloid leukaemia. Reduced phosphatase activity was found in 5 cases and peroxidase activity in 3 cases of myelodysplasia syndromes. No evident correlation was noted between the activity of these enzymes and prognosis. Increased proportion of peroxidase-negative granulocytes was observed, moreover, in most cases of chronic myeloid leukaemia. The observations will be continued in larger material.

Alkaline Phosphatase↗
PubMed1991

[Preliminary results of the treatment of acute leukemia with mitoxantrone].

Mitoxantrone is a new anthracenodione derivative with a high antineoplastic activity in proliferative diseases of the haemopoietic system. In the Institute of Haematology in Warsaw and in the Department of Haematology, Silesian Medical Academy in Katowice this agent was used in combination with cytarabine in 49 cases of acute leukaemia (35 with acute myeloid leukaemia and 14 with acute lymphoblastic leukaemia). The preparations used were Mitoxantrone (POLFA Works in Jelenia Góra) and Novantrone (Lederle). These agents were given intravenously in doses of 10-20 mg/m2 for 3 days in combination with cytarabine in three doses: 100 mg/m2 on days 1 through 7, and 1 g/m2 or 3 g/m2 every 12 hours on days 1 through 4 of the treatment. Complete remission was obtained in 17 cases (35%), including 13 with acute myeloid leukaemia (37%) and 4 with acute lymphoblastic leukaemia (29). The most frequent side effects were: long-lasting pancytopenia (in 100% of cases), hair loss (39%) and gastrointestinal toxicity (33%). No significant differences were noted in the effectiveness and toxicity between these two preparations. In the light of the presented results it may be accepted that the combination of mitoxantrone with cytarabine is an important advance in the treatment of acute leukaemias.

Adolescent↗
PubMed1979

[Analysis of the results of treatment of multiple myeloma].

Therapeutic results were analysed in 62 cases of multiple myeloma treated by two-stage method: I. with cyclically non-specific agents (melphalan) in each case. When this treatment was a failure the second step was given: II. cyclically specific and non-specific agents by the M-2 schedule. Good therapeutic response was obtained in 70% of cases. The mean survival time in the whole group was 35 months, and in the subgroup with good prognosis it was 44 months. Most (74%) patients with IgG M-protein responded well to treatment with cyclically non-specific agents, while only 50% of those with IgA M-protein had a good response to them.

Adult↗
PubMedDate not supplied

[Preliminary observations on the results of treating malignant lymphoma with Lycurim].

The authors gave Lycurim to 30 patients with malignant lymphoma (LLC--12 cases, Hodgkin's disease - 15 cases, reticulosarcoma - 2 cases and lymphosarcoma - 1 case). The patients were divided into three groups. Group I received only Lycurim, group II - Lycurim and prednisone, group III - Lycurim and Solcoseryl. Significant improvement was observed in 22 patients, with complete remission in 5 cases and partial in 17 cases. Leucopenia and thrombocytopenia precluding treatment were never observed in cases treated simultaneously with prednisone or Solcoseryl. The authors believe that the proportion of remissions may be increased combining Lycurim with vincristine, procarbazine and glycocorticosteroids (LOP or LOPP).

Actihaemyl↗
PubMedDate not supplied

[Prognostic value of the peroxidase index in patients with acute nonlymphoblastic leukemia].

In 91 patients with acute non-lymphoblastic leukaemia the peroxidase index was determined in blast cells or promyelocytes in bone marrow. Complete remission was obtained exclusively in patients with the value of the index 0-9% or over 69%. The duration of the remission and the survival time were significantly longer in patients with a high peroxidase index. This index may be useful for prediction of the course of acute non-lymphoblastic leukaemia in adults and its high value is associated with better prognosis.

Bone Marrow↗